NCT04684459

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 for HER2-positive Solid Tumors

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Sichuan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

CAR-T therapy has achieved unprecedented success in hematological tumors in recent years, but the progress of CAR-T cells in the treatment of solid tumors is facing difficulties. HER-2 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors. In this study, the PD-L1 inhibitory signal was transformed into an activation signal in the tumor microenvironment, and enhanced the killing activity and survival ability of CAR-T cells. The HER-2/PD-L1 dual-targeting CAR-T will be investigated in patients with HER2-positive solid tumors, and all enrolled subjects will receive HER2/PD-L1 CAR T cells via intravenous or thoracic/peritoneal cavity infusion.

Conditions

• Peritoneal Carcinoma Metastatic
• Pleural Effusion, Malignant
• HER2 Positive Malignancies

Interventions

Type	Name	Description
BIOLOGICAL	Dual-targeting HER2 and PD-L1 CAR-T cells	HER2-positive solid tumor serosal cavity infusion

Timeline

• Start date: 2021-03-12
• Primary completion: 2025-12-30
• Completion: 2025-12-30
• First posted: 2020-12-24
• Last updated: 2024-10-30

Locations

1 site across 1 country: China